APAC Uterine Cancer Drug Market - Industry Trends and Forecast to 2031

APAC Uterine Cancer Drug Market - Industry Trends and Forecast to 2031

The Asia-pacific uterine cancer drugs market is expected to reach USD 958,896.20 million by 2030 from USD 550,332.54 million in 2022, growing at a CAGR of 7.7% during the forecast period of 2023 to 2030.
Market Segmentation
Asia-pacific Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, and rest of Asia-Pacific) - Industry Trends and Forecast to 2030

Overview of Asia-pacific Uterine Cancer Drugs Market Dynamics

Driver
• Rising incidence of uterine cancer worldwide

Restraint

• High cost of uterine cancer treatment

Opportunity

• Advancement in genomic profiling and biomarker discovery

Market Players

Some of the major market players operating in the Asia-pacific uterine cancer drugs market are listed below:

• Baxter
• Eli Lilly and Company
• Hikma Pharmaceuticals PLC
• Sun Pharmaceutical Industries Ltd.
• Fresenius SE & Co. KGaA
• Viatris Inc.
• Sanofi
• Teva Pharmaceuticals USA, Inc.
• Amneal Pharmaceuticals LLC
• Merck & Co., Inc.
• GSK plc.
• Eisai Co., Ltd.
• Pfizer Inc.
• Getwell Oncology